Shandong Realcan Pharmaceutical Co Ltd (002589) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shandong Realcan Pharmaceutical Co Ltd (002589) has a cash flow conversion efficiency ratio of -0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-15.60 Million ≈ $-2.28 Million USD) by net assets (CN¥5.45 Billion ≈ $798.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Shandong Realcan Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Shandong Realcan Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Shandong Realcan Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Shandong Realcan Pharmaceutical Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Shandong Realcan Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Realcan Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tactile Systems Technology Inc
NASDAQ:TCMD
|
-0.002x |
|
Beijing Lanxum Tech Co
SHE:300010
|
-0.070x |
|
Kocaer Celik Sanayi ve Ticaret A.S.
IS:KCAER
|
-0.021x |
|
Gloria Material Technology
TWO:5009
|
0.023x |
|
Invesco Value Municipal Income Closed Fund
NYSE:IIM
|
0.018x |
|
Delixi Xinjiang Transp Co Ltd
SHG:603032
|
0.024x |
|
AmRest Holdings SE
MC:EAT
|
0.278x |
|
Tungkong Inc
SHE:002117
|
0.051x |
Annual Cash Flow Conversion Efficiency for Shandong Realcan Pharmaceutical Co Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see 002589 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥5.42 Billion ≈ $793.52 Million |
CN¥13.76 Million ≈ $2.01 Million |
0.003x | -90.99% |
| 2024-12-31 | CN¥5.69 Billion ≈ $833.30 Million |
CN¥160.44 Million ≈ $23.48 Million |
0.028x | +92.59% |
| 2023-12-31 | CN¥5.64 Billion ≈ $824.87 Million |
CN¥82.47 Million ≈ $12.07 Million |
0.015x | -83.91% |
| 2022-12-31 | CN¥5.75 Billion ≈ $841.67 Million |
CN¥523.07 Million ≈ $76.54 Million |
0.091x | +99.01% |
| 2021-12-31 | CN¥9.69 Billion ≈ $1.42 Billion |
CN¥442.95 Million ≈ $64.82 Million |
0.046x | +6.19% |
| 2020-12-31 | CN¥9.64 Billion ≈ $1.41 Billion |
CN¥414.96 Million ≈ $60.72 Million |
0.043x | -78.93% |
| 2019-12-31 | CN¥10.25 Billion ≈ $1.50 Billion |
CN¥2.09 Billion ≈ $306.49 Million |
0.204x | +1245.34% |
| 2018-12-31 | CN¥11.31 Billion ≈ $1.65 Billion |
CN¥-201.66 Million ≈ $-29.51 Million |
-0.018x | +92.88% |
| 2017-12-31 | CN¥9.67 Billion ≈ $1.42 Billion |
CN¥-2.42 Billion ≈ $-354.40 Million |
-0.250x | -6.78% |
| 2016-12-31 | CN¥7.50 Billion ≈ $1.10 Billion |
CN¥-1.76 Billion ≈ $-257.40 Million |
-0.234x | -71.19% |
| 2015-12-31 | CN¥3.40 Billion ≈ $498.16 Million |
CN¥-466.26 Million ≈ $-68.23 Million |
-0.137x | -52.79% |
| 2014-12-31 | CN¥1.83 Billion ≈ $267.10 Million |
CN¥-163.62 Million ≈ $-23.94 Million |
-0.090x | +46.11% |
| 2013-12-31 | CN¥1.65 Billion ≈ $241.45 Million |
CN¥-274.46 Million ≈ $-40.16 Million |
-0.166x | +10.61% |
| 2012-12-31 | CN¥916.39 Million ≈ $134.10 Million |
CN¥-170.52 Million ≈ $-24.95 Million |
-0.186x | +67.99% |
| 2011-12-31 | CN¥817.11 Million ≈ $119.57 Million |
CN¥-475.03 Million ≈ $-69.51 Million |
-0.581x | -343.92% |
| 2010-12-31 | CN¥296.03 Million ≈ $43.32 Million |
CN¥70.56 Million ≈ $10.32 Million |
0.238x | -9.07% |
| 2009-12-31 | CN¥234.18 Million ≈ $34.27 Million |
CN¥61.38 Million ≈ $8.98 Million |
0.262x | +158.80% |
| 2008-12-31 | CN¥111.89 Million ≈ $16.37 Million |
CN¥-49.88 Million ≈ $-7.30 Million |
-0.446x | -- |
About Shandong Realcan Pharmaceutical Co Ltd
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materi… Read more